Kinaset Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

-Company developing inhaled therapeutics to address significant unmet needs in respiratory diseases-

BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced its participation in the 42^nd Annual J.P. Morgan Healthcare Conference being held January 8-11, 2024 in San Francisco, CA. Members of Kinaset’s executive team are available for one-on-one investor and partner meetings.

“At Kinaset, we’re working tirelessly to advance our KN-002 program for all patients with moderate to severe asthma who remain underserved by currently available therapeutics,” said Robert Clarke, PhD, Chief Executive Officer of Kinaset. “We are ramping up for an exciting, milestone-rich 2024, with plans to debut outcomes data from the Phase 1 evaluation of our lead candidate, KN-002, at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in February. In parallel, we continue to prepare for our planned Phase 2 trial in patients with eosinophilic and non-eosinophilic mediated moderate to severe asthma. I look forward to sharing our latest progress at the J.P. Morgan Healthcare Conference and continuing to advance our pipeline of inhaled therapeutics throughout 2024.”

For additional information or to request a meeting at the J.P. Morgan Healthcare Conference, please contact the Kinaset team here.

About Kinaset Therapeutics, Inc.

Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. The Company’s lead clinical candidate KN-002 is a novel, pan-JAK inhibitor formulated as a dry powder for delivery via the non-invasive oral inhaled route of administration. KN-002 is currently being evaluated in a Phase 1b clinical study involving patients with mild to severe asthma and those with COPD (NCT05006521). With founding investors 5AM Ventures, Atlas Venture and Gimv, the Company is pursuing a patient-focused approach to build a leading respiratory therapeutics company. See more information at the Company’s website.